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功能的 MTX 与具有不同抗癌作用位点的 MMC 相结合，设计了一种新型的双载
药壳聚糖纳米靶向给药系统，并对其缓释、靶向作用和抗癌效果进行了研究。 
主要研究内容：（1）制备研究：通过“双交联绿色合成法”制备靶向性双载































Clinical studies show shortcomings of cancer chemotherapy, such as frequent 
administration, poor selectivity and high toxicity. Therefore, improving drug targeting 
and curative effect becomes an important topic, and we want to build an ideal nano 
drugs delivery system, which has sustained release effect, significant targeting and 
synergistic anticancer effect. So, we propose a new strategy which is using 
methotrexate’s two functions, targeting and anti-tumor, and the effect synergistic 
therapy to design a chitosan-based nano-targeted dual-drugs delivery system. 
The main contents are: (1) Preparation research: Using "composite cross-linking 
synthetic method" to prepare a stable, high biocompatible, chitosan-based, targeted, 
and dual-drugs-loaded nano-system and using DLS, SEM, FTIR and UV to 
characterize the sizes, surface morphologies, chemical structures, DC and EE. (2) 
Targeting research: Using CLSM to observe Hela cells’ uptake, and using in vivo 
fluorescence imaging and organ distribution experiments to observe NPs’ distribution 
in tissues. (3) Anti-tumor efficacy: Dual-drugs-loaded NPs’ release behaviors in vitro 
were observed; NPs’ cytotoxicity and Hela cells’ inhibition rate were characterized; 
Tumor’s inhibition rate and anti-tumor effect were studied by animal experiments. 
The main results are: (1) A stable, high biocompatible chitosan-based targeted 
dual-drugs-loaded nano-delivery system was prepared. Results show that CS-NPs 
have relatively uniform sizes, good absorption, and higher levels of loading drugs. (2) 
The systems have good initiative targeting. MTX can improve Hela cells’ uptake. 
Organ distribution in vivo imaging experiments further indicate that MTX-modified 
NPs have active targeting. (3) The in vitro release experiments show that the systems 
have good release effect and biphasic release characteristics; MTT tests show that 
NPs’ cytotoxicity is concentration-dependent and time-dependent; MTT tests and 
animal experiments indicate that the systems have good synergistic anticancer effect 
and strong synergistic anticancer effect, and are better than targeted 
single-drug-loaded ones.  
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异构酶的作用，影响 DNA 合成，引起 DNA 断链；通过损伤纺锤体，使有丝分
裂停滞；其它类型的作用机制[5]。 
其中，抗代谢类药物（如：甲氨蝶呤和氟尿嘧啶）通过阻碍脱氧核苷酸合成，
抑制 DNA 合成，主要杀伤处于 S 期的肿瘤细胞，属于细胞周期时相特异性抗肿
瘤药物[6]；各种烷化剂或类烷化剂（如：氮芥和丝裂霉素）通过烷化作用或类烷
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